百济神州是外企还是国企

Zymeworks, in collaboration with BeiGene, developed
ZW49, a bispecific ADC targeting HER2 with enhanced efficacy compared to first-generation ADCs, showing superior clinical outcomes. This drug is currently undergoing Phase I clinical trials for HER2-expressing cancer patients. TOPO1i ADC ...